Pharmacological characterization of a novel Kv7 potassium channels activator identified through a drug repurposing strategy
Giusy Carleo, Lidia Carotenuto, Oliver Keminer, Andrea Zaliani, Francesco Miceli, Antonio Leo, Rita Citraro, Sarah Weckhuysen, Giovambattista De Sarro, Philip Gribbon, Maurizio Taglialatela · FENS Forum 2024
Kv7.2 and Kv7.3 are voltage-gated potassium channels subunits mainly expressed in neurons where they underlie the M-current (IKM), a sub-threshold K+ current controlling action potentials generation and frequency. The Kv7.2/7.3 channel opener retigabine is an antiseizures drug used until 2017 when it was withdrawn from the market for safety reasons. Since then, no Kv7 activator is currently available for clinical use. We used a drug repurposing strategy to identify novel Kv7.2/3 activators. A library of 5600 compounds, mostly represented by clinically-approved drugs, was screened in CHO cells
ePoster · Neuroscience